Tag: phenobarbital market research

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Phenobarbital Market Growth From $1.61 Billion In 2026 To $1.96 Billion By 2030 At A CAGR Of 5%#_x000D_

The phenobarbital market size has shown consistent expansion over recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.9%. The market’s historical development can be attributed to its enduring clinical effectiveness, its extensive inclusion in essential medicine inventories, the significant occurrence of epilepsy, its utilization in neonatal treatment, and its economical pricing compared to more modern pharmaceuticals._x000D_

_x000D_

The phenobarbital market is projected to experience consistent expansion over the upcoming years. Its value is anticipated to reach $1.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.0%. This anticipated growth is driven by several factors, including sustained demand in low-resource environments, the increase in generic manufacturing, the expansion of neonatal intensive care units, an uptick in epilepsy diagnosis rates, and an emphasis on access to essential medicines. Key trends expected during this period involve its ongoing application in managing epilepsy and neonatal seizures, the increasing accessibility of generic phenobarbital, a heightened focus on affordable anticonvulsant treatments, the broader implementation of hospital-based seizure management strategies, and enhanced surveillance of long-term drug safety._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=30253413&type=smp&name=Phenobarbital%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Phenobarbital Market Growth Momentum: What Factors Are Shaping Demand?#_x000D_

The rising occurrence of epilepsy is projected to drive the expansion of the phenobarbital market in the future. This neurological condition, epilepsy, is defined by repeated, unprovoked seizures stemming from unusual electrical activity within the brain. The growing incidence of epilepsy can be attributed to enhanced awareness, with a greater number of individuals identifying symptoms and pursuing medical evaluation, resulting in an increase in documented cases. Phenobarbital proves beneficial for epilepsy because it is an anticonvulsant drug that functions by reducing the activity of brain neurons, thereby assisting in the prevention and management of seizures. As an illustration, in February 2024, data from the World Health Organization, an international public health agency located in Switzerland, indicated that approximately 50 million people worldwide suffered from epilepsy, underscoring its status as among the most widespread neurological conditions globally. Consequently, the expanding occurrence of epilepsy is anticipated to stimulate the growth of the phenobarbital market._x000D_

_x000D_

#Phenobarbital Market Segment Performance And Emerging Opportunities#_x000D_

The phenobarbital market covered in this report is segmented – _x000D_

_x000D_

1) By Indication: Epilepsy, Neonatal Seizures_x000D_

2) By Dosage Forms: Tablets, Capsules, Injectables_x000D_

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome_x000D_

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy_x000D_

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections_x000D_

_x000D_

#Phenobarbital Market Trends Redefining Industry Growth#_x000D_

Leading companies in the phenobarbital market are concentrating on developing innovative solutions, such as phenobarbital sodium, to improve the effectiveness and safety of treatments. Phenobarbital sodium refers to the sodium salt form of phenobarbital, a medication primarily employed as an anticonvulsant and sedative. It is frequently prescribed to manage seizures, particularly in conditions like epilepsy, and also to address anxiety and insomnia, sometimes being used to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., which is the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is benzyl alcohol-free and propylene glycol-free, enhancing its safety for use in newborns. SEZABY obtained orphan drug designation and is supported by clinical data demonstrating its effective control of neonatal seizures, thereby addressing a critical unmet need within this vulnerable patient population._x000D_

_x000D_

#Phenobarbital Market Key Players: Which Companies Lead Industry Competition?#_x000D_

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd. _x000D_

_x000D_

#View The Full Phenobarbital Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/phenobarbital-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Phenobarbital Market Geographic Landscape: Which Region Leads Industry Growth?#_x000D_

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Phenobarbital Market Size, Value And Growth Trends Through 2030

The phenobarbital market has experienced consistent expansion over recent years, with projections indicating an increase from $1.54 billion in 2025 to $1.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.9%. This historical growth has been driven by factors such as its proven clinical effectiveness over time, broad inclusion in essential medicine lists, a high incidence of epilepsy, application in neonatal treatment, and lower cost relative to more modern pharmaceutical options.

The phenobarbital sector is anticipated to experience consistent growth over the coming years, reaching a valuation of $1.96 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.0%. This forecasted expansion is largely influenced by persistent demand in areas with limited healthcare resources, a rise in generic drug production, an increase in neonatal intensive care units, higher epilepsy diagnosis rates, and a heightened emphasis on ensuring access to essential medications. Key developments expected during this period include the ongoing application of phenobarbital for managing epilepsy and neonatal seizures, a broader availability of its generic versions, a stronger focus on cost-effective anticonvulsant treatments, an expansion of seizure care within hospital settings, and more rigorous monitoring of long-term medication safety.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Phenobarbital Market Demand Drivers Creating New Revenue Opportunities

The phenobarbital market is anticipated to experience growth driven by the rising incidence of epilepsy. This neurological condition involves recurring, spontaneous seizures stemming from irregular electrical impulses in the brain. Heightened awareness has led more individuals to recognize symptoms and pursue medical evaluation, resulting in a higher number of diagnosed cases, which accounts for the growing prevalence. As an anticonvulsant, phenobarbital aids in managing epilepsy by reducing neuronal activity in the brain, thereby preventing and controlling seizure episodes. Data from the World Health Organization, a Switzerland-based international public health agency, revealed in February 2024 that approximately 50 million people globally were affected by epilepsy, underscoring its status as a prevalent neurological disease. Consequently, the upward trend in epilepsy cases is expected to drive expansion within the phenobarbital market.

Phenobarbital Market Segment Analysis Highlighting Growth Areas

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Phenobarbital Market Trends Driving Strategic Industry Expansion

Key players in the phenobarbital market are concentrating on creating advanced solutions, like phenobarbital sodium, to improve treatment efficacy and safety. Phenobarbital sodium is the sodium salt variant of phenobarbital, a drug mainly utilized as an anticonvulsant and sedative. It is frequently prescribed for seizure management, especially in epilepsy, along with treating anxiety and insomnia, and occasionally inducing sedation prior to medical procedures. For example, in January 2023, Sun Pharmaceutical Industries Ltd., a pharmaceutical firm based in India, introduced SEZABY (phenobarbital sodium) in the United States, marking the first and only FDA-approved medication specifically designed for seizure treatment in both term and preterm neonates. This formulation excludes benzyl alcohol and propylene glycol, enhancing its safety for newborns. SEZABY has been granted orphan drug status and is supported by clinical evidence demonstrating its effectiveness in controlling neonatal seizures, thereby addressing a significant unmet need within this vulnerable group.

Phenobarbital Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Access The Complete Phenobarbital Market Report:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Phenobarbital Market Geographic Distribution And Regional Opportunities

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Phenobarbital Market Projected To Expand During 2026–2030?

The phenobarbital market size has seen continuous growth over recent years. Its expansion is anticipated to take it from $1.54 billion in 2025 to $1.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.9%. This past growth can be linked to factors such as its enduring clinical effectiveness, broad inclusion in lists of essential medicines, the high incidence of epilepsy, its application in neonatal care, and its affordability compared to more modern drugs.

The phenobarbital market size is anticipated to undergo steady expansion in the coming years. It is expected to climb to $1.96 billion in 2030, achieving a compound annual growth rate (CAGR) of 5.0%. The projected increase during this period can be attributed to ongoing demand in low-resource environments, the broadening of generic manufacturing, an rise in neonatal intensive care units, increasing rates of epilepsy diagnosis, and a focus on ensuring access to essential medicines. Significant developments anticipated during the forecast period include the continued application in epilepsy and neonatal seizure treatment, enhanced availability of generic phenobarbital, a growing emphasis on cost-effective anticonvulsant therapies, the expansion of hospital-based seizure management, and increased monitoring of long-term drug safety.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Important Drivers Are Powering The Phenobarbital Market Growth?

The anticipated expansion of the phenobarbital market is linked to the rising occurrence of epilepsy. This neurological condition is characterized by recurrent, unprovoked seizures, originating from abnormal electrical activity within the brain. The growing prevalence of epilepsy is due to improved awareness, as more individuals are recognizing symptoms and seeking medical diagnoses, leading to a higher number of reported cases. Phenobarbital is effective for epilepsy because it is an anticonvulsant medication that operates by slowing down the activity of the brain’s neurons, aiding in the prevention and control of seizures. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international public health agency, around 50 million people worldwide were living with epilepsy, affirming its position as one of the most common neurological diseases globally. Consequently, the increasing prevalence of epilepsy is projected to propel the growth of the phenobarbital market.

What Segment Types Are Included In The Phenobarbital Market Analysis?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Which Trends Are Influencing The Direction Of The Phenobarbital Market?

Companies operating within the phenobarbital market are prioritizing the development of innovative solutions, such as phenobarbital sodium, to enhance the effectiveness and safety of treatments. Phenobarbital sodium refers to the sodium salt form of phenobarbital, a medication primarily utilized as an anticonvulsant and sedative. It is commonly prescribed for managing seizures, particularly in conditions like epilepsy, as well as for treating anxiety and insomnia, and sometimes for inducing sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., which is the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is benzyl alcohol-free and propylene glycol-free, thereby enhancing its safety for use in newborns. SEZABY received orphan drug designation and is supported by clinical data demonstrating its effective control of neonatal seizures, addressing a critical unmet need in this vulnerable patient population.

Which Firms Are Competing In The Phenobarbital Market?

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Access The Complete Phenobarbital Market Report:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Which Region Is The Primary Market For The Phenobarbital Market?

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Phenobarbital Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

Browse Through More Reports Similar to the Global Phenobarbital Market 2026, By The Business Research Company

Phenolic Panel Market Report 2026

https://www.thebusinessresearchcompany.com/report/phenolic-panel-global-market-report

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Phenobarbital Market Compare Between 2026 And 2030?

The phenobarbital market has shown consistent expansion in recent years. Its size is expected to increase from $1.54 billion in 2025 to $1.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.9%. The market’s past growth was driven by its enduring clinical effectiveness, broad inclusion in essential medicine lists, the high occurrence of epilepsy, its application in neonatal intensive care, and its more affordable price point compared to newer treatments.

The phenobarbital market size is projected to experience consistent growth in the coming years, with expectations to reach $1.96 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.0%. This anticipated expansion over the forecast period is fueled by several factors, including sustained demand in low-resource settings, the broadening of generic manufacturing, an increase in neonatal intensive care units, rising rates of epilepsy diagnosis, and a concentrated effort on ensuring access to essential medicines. Prominent trends for the forecast period involve the drug’s continued application in managing epilepsy and neonatal seizures, an expanding availability of generic phenobarbital, an increasing emphasis on cost-effective anticonvulsant therapies, the growth of hospital-based seizure management services, and enhanced monitoring of long-term drug safety.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Key Factors Are Shaping The Phenobarbital Market Landscape?

The phenobarbital market is expected to expand due to the rising prevalence of epilepsy, a neurological disorder marked by recurrent, unprovoked seizures originating from abnormal electrical activity in the brain. This increase in epilepsy cases is largely attributed to greater awareness, prompting more individuals to recognize symptoms and seek medical diagnosis, thereby leading to higher reported instances. Phenobarbital is effective for epilepsy as it functions as an anticonvulsant medication that slows down the activity of brain neurons, aiding in seizure prevention and control. For example, in February 2024, the World Health Organization, a Switzerland-based international public health agency, indicated that around 50 million people globally were living with epilepsy, reinforcing its position as one of the most common neurological diseases worldwide. Consequently, the growing prevalence of epilepsy is anticipated to propel the growth of the phenobarbital market.

Which Segment Classifications Are Used In The Phenobarbital Market Segment Analysis?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Which Trends Are Impacting The Progress Of The Phenobarbital Market?

Leading companies operating in the phenobarbital market are focusing on developing innovative solutions, such as phenobarbital sodium, to enhance the effectiveness and safety of treatments. Phenobarbital sodium refers to the sodium salt form of phenobarbital, a medication primarily used as an anticonvulsant and sedative. It is commonly prescribed to manage seizures, particularly in conditions such as epilepsy, as well as to treat anxiety and insomnia and sometimes to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is benzyl alcohol-free and propylene glycol-free, making it safer for use in newborns. SEZABY received orphan drug designation and is backed by clinical data showing it effectively controls neonatal seizures, addressing a critical unmet need in this vulnerable patient population.

Which Firms Are Contributing To The Phenobarbital Market Ecosystem?

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Get The Full Phenobarbital Market Report:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Which Region Is The Top Contributor To The Phenobarbital Market By Share?

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Phenobarbital Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Browse Through More Reports Similar to the Global Phenobarbital Market 2026, By The Business Research Company

Phenolic Panel Market Report 2026

https://www.thebusinessresearchcompany.com/report/phenolic-panel-global-market-report

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Phenobarbital Market Over The Period 2026–2030?

The phenobarbital market has experienced consistent growth over the past few years. It is projected to expand from $1.54 billion in 2025 to reach $1.62 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.9%. Historically, this expansion has been driven by its proven long-term clinical effectiveness, widespread availability on essential medicine lists, the high prevalence of epilepsy, its application in neonatal care, and its affordability compared to newer medications.

The phenobarbital market is projected to experience consistent expansion over the next few years. By 2030, its valuation is expected to reach $1.96 billion, advancing at a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period is primarily driven by factors such as sustained demand in resource-limited environments, the broadening of generic manufacturing, an increase in neonatal intensive care units, escalating epilepsy diagnosis rates, and a strong emphasis on access to essential medicines. Furthermore, major trends in the forecast period include its continued application in managing epilepsy and neonatal seizures, the increasing availability of generic phenobarbital, a growing emphasis on cost-effective anticonvulsant therapies, the expansion of hospital-based seizure management services, and rising vigilance concerning long-term drug safety.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Drivers Are Expected To Influence The Phenobarbital Market During The Forecast Period?

The projected expansion of the phenobarbital market is intrinsically linked to the increasing occurrence of epilepsy. This neurological disorder is characterized by recurrent, unprovoked seizures that arise from atypical electrical activity within the brain. The observed rise in epilepsy prevalence is largely due to improved awareness, as more people are now recognizing symptoms and seeking professional medical diagnoses, which in turn leads to a greater number of reported cases. Phenobarbital is beneficial for epilepsy treatment as it is an anticonvulsant medication designed to reduce the activity of the brain’s neurons, thereby assisting in both the prevention and control of seizures. As an illustration, in February 2024, the World Health Organization, a Switzerland-based international public health agency, indicated that around 50 million people worldwide were living with epilepsy, underscoring its standing as one of the most prevalent neurological diseases globally. Thus, the growing prevalence of epilepsy is expected to fuel the growth of the phenobarbital market.

How Is The Phenobarbital Market Divided Into Its Major Segments?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

How Are Trends Transforming The Phenobarbital Market Landscape?

Major companies in the phenobarbital market are directing their efforts toward developing novel solutions, such as phenobarbital sodium, to bolster the effectiveness and safety of treatments. Phenobarbital sodium is identified as the sodium salt form of phenobarbital, a medication primarily employed for its anticonvulsant and sedative properties. It is frequently prescribed for the control of seizures, particularly in conditions like epilepsy, in addition to treating anxiety and insomnia, and sometimes for inducing sedation before medical procedures. As an illustration, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S. This product represents the first and only FDA-approved medication specifically designated for managing seizures in both term and preterm neonates. This new formulation is free of benzyl alcohol and propylene glycol, rendering it safer for use in newborns. SEZABY obtained orphan drug designation and is substantiated by clinical data confirming its efficacy in controlling neonatal seizures, thereby addressing a crucial unmet need within this vulnerable patient population.

Who Are The Prominent Organizations Shaping The Phenobarbital Market?

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Read the full phenobarbital market report here:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Which Region Is Forecast To Lead The Phenobarbital Market In Terms Of Market Size?

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Phenobarbital Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

Browse Through More Reports Similar to the Global Phenobarbital Market 2026, By The Business Research Company

Phenolic Panel Market Report 2026

https://www.thebusinessresearchcompany.com/report/phenolic-panel-global-market-report

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the phenobarbital market from 2026–2035 with trusted insights from The Business Research Company

How much is the Phenobarbital Market valued at in 2026, and what valuation is forecast for 2030?

The phenobarbital market size has exhibited consistent growth in recent years. It is anticipated to increase from $1.54 billion in 2025 to $1.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.9%. The expansion observed historically can be attributed to its long-standing clinical efficacy, widespread availability in essential medicine lists, the high prevalence of epilepsy, its use in neonatal care, and its affordability compared to newer drugs.

The phenobarbital market size is projected to experience consistent expansion over the upcoming years. It is anticipated to reach $1.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.0%. Factors contributing to this growth during the forecast period include sustained demand in areas with limited resources, an increase in generic manufacturing, the expansion of neonatal intensive care units, an uptick in epilepsy diagnosis rates, and an emphasis on access to essential medicines. Key trends expected in the forecast period encompass its ongoing application in epilepsy and neonatal seizure management, the broader availability of generic phenobarbital, an intensified focus on economical anticonvulsant treatments, the broadening of hospital-based seizure care, and heightened oversight of long-term drug safety.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Drivers Are Influencing The Growth Of The Phenobarbital Market?

The anticipated expansion of the phenobarbital market is projected to be driven by the rising occurrence of epilepsy. This neurological condition, epilepsy, is characterized by recurrent, unprovoked seizures that arise from abnormal electrical activity in the brain. The growing incidence of epilepsy is attributed to enhanced awareness, as more individuals recognize symptoms and seek medical diagnoses, leading to a greater number of reported cases. Phenobarbital is beneficial for epilepsy as it functions as an anticonvulsant medication, slowing down the activity of brain neurons to help prevent and manage seizures. For instance, in February 2024, the World Health Organization, a Switzerland-based international public health agency, reported that approximately 50 million people worldwide were living with epilepsy, underscoring its status as one of the globe’s most prevalent neurological diseases. Consequently, the increasing prevalence of epilepsy is expected to propel the growth of the phenobarbital market.

What Segments Are Included Within The Phenobarbital Market?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Which Trends Are Influencing The Development Of The Phenobarbital Market?

Major companies operating in the phenobarbital market are focusing on developing innovative solutions, such as phenobarbital sodium, to enhance the effectiveness and safety of treatments. Phenobarbital sodium refers to the sodium salt form of phenobarbital, a medication primarily used as an anticonvulsant and sedative. It is commonly prescribed to manage seizures, particularly in conditions such as epilepsy, as well as to treat anxiety and insomnia and sometimes to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is benzyl alcohol-free and propylene glycol-free, making it safer for use in newborns. SEZABY received orphan drug designation and is backed by clinical data showing it effectively controls neonatal seizures, addressing a critical unmet need in this vulnerable patient population.

Who Are The Core Companies Influencing Trends In The Phenobarbital Market?

Major companies operating in the phenobarbital market are Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Fresenius Kabi AG, Baxter International Inc., Par Pharmaceutical Inc., Harman Finochem Ltd., Manus Aktteva Biopharma LLP, Shandong Xinhua Pharmaceutical Co. Ltd., Alkaloida Chemical Company Zrt., Yashiro Pharmaceutical Co. Ltd., JPN Pharma Pvt. Ltd., Pfizer CentreOne, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Which Regions Are Projected To Dominate The Phenobarbital Market In The Coming Years?

North America was the largest region in the phenobarbital market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Phenobarbital Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

Browse Through More Reports Similar to the Global Phenobarbital Market 2026, By The Business Research Company

Phenolic Panel Market Report 2026

https://www.thebusinessresearchcompany.com/report/phenolic-panel-global-market-report

Phosgene Market Report 2026

https://www.thebusinessresearchcompany.com/report/phosgene-global-market-report

Anticholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the phenobarbital market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present Size Of The Phenobarbital Market And What Value Is Projected For 2029?

The phenobarbital market size has exhibited consistent expansion over recent years. It is projected to grow from $1.47 billion in 2024 to $1.54 billion in 2025, progressing at a compound annual growth rate (CAGR) of 4.4%. The factors contributing to this historic growth include its extensive application in epilepsy management, the widespread occurrence of epilepsy and seizure disorders, government supply initiatives, increasing demand within veterinary applications, and sustained efforts toward universal health coverage.

The phenobarbital market is anticipated to show consistent expansion in the coming years. Its value is projected to reach $1.87 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.9%. This expected growth during the forecast period can be attributed to several factors, including the increasing production of generic drugs, a heightened focus on managing neurological diseases, the expansion of digital supply chains and e-pharmacy services, regulatory adjustments that support the use of generics, and the stable nature of regulatory pathways for generic medicines. Significant trends for the forecast period include the creation of easy-to-administer delivery methods, ongoing innovation in research and development, the introduction of extended-release formulations, improved drug delivery systems, and investments aimed at enhancing production techniques.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Factors Are Boosting The Phenobarbital Market?

The rising incidence of epilepsy is anticipated to drive the growth of the phenobarbital market moving forward. Epilepsy is a neurological condition characterized by recurrent, unprovoked seizures caused by abnormal electrical activity within the brain. The increasing prevalence of epilepsy is attributed to improved awareness, as more individuals recognize symptoms and seek medical diagnoses, leading to a higher number of reported cases. Phenobarbital is beneficial for epilepsy because it is an anticonvulsant medication that functions by reducing the activity of brain neurons, which helps to prevent and control seizures. For example, in May 2024, a report from the Centers for Disease Control and Prevention, a US-based government agency, stated that between 2021 and 2022, approximately 2.9 million adults in the U.S. were living with active epilepsy, constituting about 1% of the adult population. Consequently, the growing prevalence of epilepsy is expected to propel the growth of the phenobarbital market.

What Are The Core Segmentation Criteria In The Phenobarbital Market?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Which Emerging Trends Are Reshaping The Phenobarbital Market Landscape?

Companies active in the phenobarbital market are concentrating on developing innovative solutions, such as phenobarbital sodium, with the goal of enhancing the effectiveness and safety of treatments. Phenobarbital sodium is identified as the sodium salt form of phenobarbital, a medication chiefly employed as an anticonvulsant and sedative. It is frequently prescribed for the management of seizures, particularly in conditions like epilepsy, as well as for treating anxiety and insomnia, and sometimes for inducing sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., which is the first and only FDA-approved medication specifically designated for addressing seizures in both term and preterm neonates. This new formulation is free of benzyl alcohol and propylene glycol, thereby making it safer for administration to newborns. SEZABY received orphan drug designation and is supported by clinical data confirming its efficacy in controlling neonatal seizures, addressing a significant unmet need in this vulnerable patient group.

Which Players Are Shaping The Competitive Landscape Of The PhenobarbitalXX Market?

Major companies operating in the phenobarbital market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, H. Lundbeck A/S, Sandoz Group AG, Yashiro Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Par Pharmaceutical Inc., Shandong Xinhua Pharmaceutical Co. Ltd., Manus Aktteva Biopharma LLP, JPN Pharma Pvt. Ltd., Alkaloida Chemical Company Zrt., Harman Finochem Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

What Regional Trends Are Shaping Growth In The Phenobarbital Market?

North America was the largest region in the phenobarbital market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

Browse Through More Reports Similar to the Global Phenobarbital Market 2025, By The Business Research Company

Anti Viral Drug Therapy Market 2025

https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market

Artificial Intelligence Ai In Drug Discovery Market 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-drug-discovery-market

Artificial Intelligence In Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Phenobarbital Market Expected To Become By 2029 Compared With Its 2025 Level?

The phenobarbital market has experienced consistent expansion in recent times. Projections indicate it will expand from $1.47 billion in 2024 to $1.54 billion in 2025, showing a compound annual growth rate (CAGR) of 4.4%. Historically, this expansion has been driven by its extensive application in epilepsy treatment, the common occurrence of epilepsy and seizure conditions, state-sponsored supply initiatives, increasing requirements in animal medicine, and drives towards comprehensive healthcare access.

The phenobarbital market is anticipated to show consistent expansion in the coming years. It is projected to achieve a size of $1.87 billion by 2029, with a compound annual growth rate (CAGR) of 4.9%. This growth throughout the forecast period can be attributed to factors such as the increasing production of generic drugs, a greater focus on managing neurological diseases, the expansion of digital supply chains and e-pharmacy platforms, regulatory changes that support the use of generics, and stable regulatory pathways for generic medications. Prominent trends for the forecast period include the development of easier-to-administer delivery methods, ongoing innovation in research and development, the creation of extended-release formulations, enhancements in drug delivery systems, and investments aimed at improving production techniques.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Are The Drivers Pushing New Developments In The Phenobarbital Market?

The increasing prevalence of epilepsy is projected to bolster the growth of the phenobarbital market in the foreseeable future. This neurological disorder is characterized by recurring, unprovoked seizures that arise from atypical electrical activity within the brain. The rise in epilepsy’s prevalence can be attributed to improved awareness, as more individuals recognize symptoms and seek medical diagnoses, resulting in a greater number of reported cases. Phenobarbital proves beneficial for epilepsy treatment as an anticonvulsant medication that operates by moderating the activity of the brain’s neurons, thereby assisting in the prevention and control of seizures. For instance, in May 2024, a report published by the Centers for Disease Control and Prevention, a US-based government agency, revealed that between 2021 and 2022, approximately 2.9 million adults in the U.S. were living with active epilepsy, which constituted about 1% of the adult population. Thus, the rising incidence of epilepsy is anticipated to propel the phenobarbital market’s expansion.

How Is The Phenobarbital Market Segmented?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

What Key Innovation Trends Are Fueling Advancements In The Phenobarbital Market?

Leading companies in the phenobarbital market are concentrating on developing innovative solutions, such as phenobarbital sodium, to enhance treatment effectiveness and safety. Phenobarbital sodium is the sodium salt form of phenobarbital, a medication primarily used as an anticonvulsant and sedative. It is commonly prescribed to manage seizures, particularly in conditions like epilepsy, as well as to treat anxiety and insomnia, and sometimes to induce sedation before medical procedures. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S., making it the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates. This new formulation is free of benzyl alcohol and propylene glycol, making it safer for use in newborns. SEZABY received orphan drug designation and is supported by clinical data demonstrating its effectiveness in controlling neonatal seizures, thereby addressing a critical unmet need in this vulnerable patient population.

Which Leading Companies Dominate The Phenobarbital Market Share?

Major companies operating in the phenobarbital market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, H. Lundbeck A/S, Sandoz Group AG, Yashiro Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Par Pharmaceutical Inc., Shandong Xinhua Pharmaceutical Co. Ltd., Manus Aktteva Biopharma LLP, JPN Pharma Pvt. Ltd., Alkaloida Chemical Company Zrt., Harman Finochem Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

Which Region Is Projected To Lead The Phenobarbital Market During The Forecast Period?

North America was the largest region in the phenobarbital market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Phenobarbital Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

Browse Through More Reports Similar to the Global Phenobarbital Market 2025, By The Business Research Company

Anti Viral Drug Therapy Market 2025

https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market

Artificial Intelligence Ai In Drug Discovery Market 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-drug-discovery-market

Artificial Intelligence In Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Phenobarbital Market Growth Evolved From 2024 To 2025, And What’s Ahead?

Over the past few years, the phenobarbital market has experienced a consistent expansion. The market size, which was valued at $1.47 billion in 2024, is projected to surge to $1.54 billion in 2025, growing at a Compound Annual Growth Rate (CAGR) of 4.4%. Factors that contributed to the growth in the historic period include its wide-ranging use in managing epilepsy, the increasing incidence of epilepsy and seizure disorders, government-led supply programs, the escalating demand in veterinary applications, and initiatives towards achieving universal health coverage.

Continued expansion is anticipated in the phenobarbital market over the coming years, with an expected valuation of $1.87 billion by 2029 and a compound annual growth rate (CAGR) of 4.9%. The projected growth over the forecast period could be due to factors such as the growth of the generic drug manufacturing industry, increased attention towards managing neurological diseases, advancements in digital supply chains and e-pharmacies, regulatory alterations promoting the use of generics, and consistent regulatory pathways for generic drugs. Future trends to look out for during the forecast period are the introduction of user-friendly drug delivery methods, innovations in R&D, the launch of extended-release formulas, the improvement of drug delivery systems, and financial allocation in enhancing production methodologies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Phenobarbital Market?

The escalating instances of epilepsy are anticipated to drive the expansion of the phenobarbital market. Epilepsy, a neurological disorder characterized by reoccurring, spontaneous seizures due to unusual brain electrical activity, is becoming more prevalent due to heightened awareness. More individuals recognize the symptoms and pursue a medical evaluation, leading to a surge in reported cases. As an anticonvulsant medication that slows down the brain’s neuron activity to prevent and control seizures, phenobarbital is valuable in epilepsy treatment. For instance, a Centers for Disease Control and Prevention report published in May 2024 revealed that about 2.9 million U.S. adults had active epilepsy between 2021 and 2022, constituting roughly 1% of the adult population. Consequently, with the increasing frequency of epilepsy, the phenobarbital market is expected to experience a surge in growth.

Which Primary Segments of the Phenobarbital Market Are Driving Growth and Industry Transformations?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Phenobarbital Market?# Market?

North America was the largest region in the phenobarbital market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Phenobarbital Market?

The key players in the phenobarbital market are emphasizing the creation of inventive resources, notably phenobarbital sodium, to bolster the efficacy and safety of therapeutic procedures. Phenobarbital sodium is the sodium salt variation of phenobarbital, which is commonly used as a sedative and anticonvulsant. It is usually employed in the management of seizures, especially for conditions like epilepsy. It is also utilized for anxiety, insomnia treatment, and at times for sedation induction before medical procedures. For example, in January 2023, Sun Pharmaceutical Industries Ltd., a pharmaceutical company based in India, introduced SEZABY (phenobarbital sodium) in the U.S. market. This was the inaugural and exclusive FDA-endorsed drug explicitly intended for managing seizures in both term and preterm neonates. The novel formulation is devoid of benzyl alcohol and propylene glycol, rendering it safer for newborns use. SEZABY obtained the orphan drug designation and clinical data support its efficient control of neonatal seizures, thus addressing a significant and unfulfilled need in this susceptible patient demographic.

View the full report here:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

What Parameters Are Used to Define the Phenobarbital Market?

Phenobarbital is a long-acting barbiturate medication most commonly used to control and prevent seizures, particularly in the treatment of epilepsy. It is sometimes prescribed as a sedative for anxiety or to manage withdrawal symptoms. It works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits nerve activity in the brain, resulting in a calming effect on the central nervous system and a reduced risk of seizures.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24377

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Are the Key Milestones in the Phenobarbital Market’s Growth Trajectory From 2025 To 2034?

In recent times, the phenobarbital market has seen a robust growth. It is projected to increase from $1.47 billion in 2024 to $1.55 billion in 2025, translating to a compound annual growth rate (CAGR) of 5.4%. Factors such as its common use in managing epilepsy, the incidence of epilepsy and seizure disorders, government initiatives for supply, increasing demand in veterinary applications, and strides towards universal health coverage drive the growth experienced during this historic period.

Over the coming years, it is anticipated that the phenobarbital market size will experience robust growth, with predictions placing it at $1.91 billion in 2029 with a 5.2% compound annual growth rate (CAGR). Various factors contributing to this projected growth during the forecast period include the growth of generic drug production, increasing emphasis on managing neurological diseases, the growth of e-pharmacies, changes in regulations supporting generic use, and the consistency in regulatory pathways for generics. The forecast period is also expected to witness trends such as the creation of user-friendly drug delivery forms, advancements in research and development, the introduction of extended-release formulations, improved drug delivery systems, and investments made to advance production methods.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Phenobarbital Market?

The phenobarbital market is projected to expand due to the rising occurrence of epilepsy. Epilepsy, a neurological disorder marked by regular, spontaneous seizures caused by erratic electrical activity within the brain, is experiencing increased prevalence due to heightened awareness. More individuals are now identifying the symptoms and proactively seeking medical help, resulting in more diagnosed cases. Phenobarbital, an anticonvulsant medication, is efficient in managing epilepsy as it decelerates the brain neurons’ activities, facilitating the prevention and control of seizures. The Centers for Disease Control and Prevention, a government agency based in the USA, reported in May 2024 that approximately 2.9 million adults in the U.S. were suffering from active epilepsy between 2021 and 2022, comprising roughly 1% of the adult population. Hence, the growing occurrence of epilepsy is anticipated to drive the phenobarbital market’s evolution.

Which Key Market Segments Comprise the Phenobarbital Market and Drive Its Revenue Growth?

The phenobarbital market covered in this report is segmented –

1) By Indication: Epilepsy, Neonatal Seizures

2) By Dosage Forms: Tablets, Capsules, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Seizure Management, Anesthesia, Sleep Disorders, Alcohol Withdrawal Syndrome

5) By End User: Hospitals, Clinics, Research Laboratories, Homecare Settings

Subsegments:

1) By Epilepsy: Focal (Partial) Seizures, Generalized Tonic-Clonic Seizures, Status Epilepticus, Refractory Epilepsy, Idiopathic Epilepsy

2) By Neonatal Seizures: Hypoxic-Ischemic Encephalopathy (HIE)-Induced Seizures, Intracranial Hemorrhage-Induced Seizures, Metabolic Disorders, Congenital Brain Malformations, Infections

Request customized data on this market:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

Which Areas Are Leading Regions in the Phenobarbital Market Expansion Across the Globe?

North America was the largest region in the phenobarbital market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the phenobarbital market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering the Phenobarbital Market Direction?

Leading businesses in the phenobarbital market are concentrating their efforts on creating inventive solutions like phenobarbital sodium to increase the safety and effectiveness of treatment procedures. Phenobarbital sodium, which is the sodium salt variation of phenobarbital, is a drug typically used for anticonvulsant and sedative purposes. It is frequently recommended for seizure management, especially in cases such as epilepsy, and for the treatment of anxiety and insomnia. It’s also sometimes used as a sedative prior to medical procedures. For example, Sun Pharmaceutical Industries Ltd., an Indian pharmaceutical firm, released SEZABY (phenobarbital sodium) in the U.S. in January 2023, the first FDA-approved drug specifically designed to treat seizures in both term and preterm infants. The new formula, which lacks benzyl alcohol and propylene glycol, is safer for newborn use. Supported by clinical data that demonstrates its effectiveness in controlling neonatal seizures, SEZABY received the orphan drug designation, thus meeting a crucially unfulfilled need in this sensitive patient group.

View the full report here:

https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

How Is the Phenobarbital Market Conceptually Defined?

Phenobarbital is a long-acting barbiturate medication most commonly used to control and prevent seizures, particularly in the treatment of epilepsy. It is sometimes prescribed as a sedative for anxiety or to manage withdrawal symptoms. It works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits nerve activity in the brain, resulting in a calming effect on the central nervous system and a reduced risk of seizures.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/customise?id=24377&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model